**SSA**Characterisation of type III effector proteins from A/E pathogens.

由大肠杆菌引起的人类感染对公共卫生造成重大负担。例如，最近的几次暴发可以追溯到与牛接触的受污染农产品，牛是某些致病性大肠杆菌的天然宿主。大肠杆菌菌株。这些细菌产生分子制剂，使它们能够靶向和操纵人类的肠道组织，导致病理学。其中一组是毒素或效应蛋白，它们由细菌通过称为III型分泌系统（T3SS）的大分子复合物注射到肠道细胞中。该项目将集中于致病性大肠杆菌产生的未表征的效应蛋白。大肠杆菌菌株，以及啮齿类柠檬酸杆菌，这是一种小鼠限制性病原体，与人类致病性大肠杆菌共享许多毒力决定因子。大肠杆菌菌株。我们的目标是确定细菌靶向的特定宿主途径，这些相互作用的分子基础，并证明效应子在小鼠感染模型中的重要性。了解这些毒素在感染中的作用对于开发新的治疗药物和有效应对疫情至关重要。

Human infections caused by Escherichia coli present a significant burden to public health. For example, several recent outbreaks can be traced back to contaminated produce that had been in contact with cattle, the natural reservoir for some pathogenic E. coli strains. These bacteria produce molecular agents that allow them to target and manipulate gut tissue in humans, leading to pathology. One group of these agents are toxins, or effector proteins, that are injected into gut cells by the bacterium via a macromolecular complex termed the type III secretion system (T3SS). This project will focus on uncharacterised effector proteins produced by pathogenic E. coli strains, as well as Citrobacter rodentium, which is a mouse-restricted pathogen that shares a number of virulence determinants with human pathogenic E. coli strains. We aim to determine the specific host pathways that are being targeted by the bacterium, the molecular basis for these interactions, and demonstrate the importance of effectors in a mouse model of infection. Understanding the role of each of these toxins in infection is critical for developing novel therapeutic agents and effectively dealing with outbreaks.